Ifosfamide and Etoposide Salvage Treatment in Advanced Ovarian Cancer
Journal of Chemotherapy1991Vol. 3(5), pp. 332–334
Citations Over Time
Milena Bruzzone, Elisabetta Campora, Laura Merlini, Simone Giudici, G Bottero, L Iskra, Michela Donadio, Ivan Vito Ferrari, Nicola Ragni
Abstract
Twelve FIGO stage III-IV ovarian cancer patients progressing or relapsing after primary cisplatin-containing combination chemotherapy were treated with ifosfamide and etoposide. Only patients with clinically evaluable disease entered the trial. The 12 patients received a median number of 3 courses (range 1-6). No complete or partial response and two disease stabilizations were observed. Ten patients progressed on therapy. The combination of ifosfamide and etoposide does not appear to be an effective salvage treatment for advanced ovarian cancer.
Related Papers
- → Anticancer activity of the combination of cisplatin and etoposide in endometrial cancer-bearing nude mice(1991)3 cited
- → Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood: A pediatric oncology group study(1993)6 cited
- → A Phase I/II Study of a 72‐h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma(1997)5 cited
- → Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors(1982)28 cited
- → Ifosfamide and etoposide as salvage therapy for non‐Hodgkin's lymphoma(1986)12 cited